Daewon to release new anti-osteoarthritis drug

Published: 2007-04-27 06:58:00

Updated: 2007-04-27 06:58:00

Daewon Pharm said on April 23 that its home-grown Peluvi tablets (felubiprofen), new NSAID (nonsteroidal anti-inflammatory drug) for treatment of osteoarthritis, was approved by the Korea Food and Drug Administration. The medication is expected to be available in the latter of this year.

Precl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK